Lilly and Hims & Hers expand self-pay access to obesity medicines
Eligible patients prescribed Zepbound or Foundayo through Hims & Hers can receive Lilly’s self-pay prices and home delivery.

The brief
- ■The agreement covers the FDA-approved medicines Zepbound and Foundayo.
- ■Self-pay pricing starts at $299 a month for Zepbound and $149 for Foundayo.
- ■A licensed provider must determine that a prescription is appropriate.
Why it matters
The agreement could simplify access for people paying without insurance, although eligibility and a licensed provider’s prescription still apply.
The full story
Eli Lilly and Hims & Hers announced Friday that eligible patients can consult a licensed provider on the Hims & Hers platform and, if prescribed, receive Zepbound or Foundayo through the service. The companies said the medicines can be shipped to patients’ homes.
The agreement uses Lilly’s self-pay pricing, which starts at $299 per month for Zepbound and $149 per month for Foundayo. Both medicines are FDA-approved, and a prescription remains necessary.
Topics
Sources
- Eli Lilly and Company
More briefs

Business
Oil Prices Rise as Traders Weigh Prospects for Middle East Settlement
2h ago · 1 min brief

Business
Tech Stock Rout Wipes Out $2.5 Trillion as Investors Reassess AI Bets
2h ago · 1 min brief

Business
South Korea moves to curb forced stock sales after Wall Street rout
2h ago · 1 min brief
